Net-zero targets: Scope 1&2 by FY2035, value chain by FY2040 Targets to reduce Scope 1&2 by 40% by FY2025, 65% by FY2030 and reach net-zero by FY2035 (vs FY2016 baseline). Scope 3: 25% reduction by FY2030, net-zero by FY2040 (vs FY2022 baseline). Aligned with SBTi Corporate Net-Zero Standard.
▾ expand
Singapore Green Mark Platinum Positive Energy certification Takeda's new manufacturing support building in Singapore earned a Green Mark Platinum Positive Energy certification — first for the biopharmaceutical industry in Singapore. Photovoltaic panels produce more energy than the building uses.
▾ expand
Joined TNFD early adopter cohort In January 2024, Takeda joined the first cohort of adopters of the Taskforce for Nature-related Financial Disclosures recommendations and committed to identify, assess and disclose nature-related dependencies, impacts, risks and opportunities by fiscal year 2026.
▾ expand
Sustainability by Design program with 10 LCAs completed Sustainability by Design Program established with 10 life-cycle assessments (LCAs) completed for high-impact products. From 2023, applying SbD framework to all new pipeline products.
▾ expand
Nature-based carbon removals for residual <10% emissions In line with SBTi Corporate Net-Zero Standard guidelines, Takeda will continue to invest in nature-based carbon removal projects, prioritizing solutions that benefit human health. Removals will address residual emissions (<10%) with high-quality, permanent carbon removals after >90% absolute reductions.
▾ expand
Dependent: Supplier engagement toward science-based targets 56% of suppliers (by emissions) have set or committed to set science-based targets, up from 45% in FY2022. Target of 67% by FY2024 and pursuing 60% reduction in suppliers' operational emissions. Goal: 25% reduction in Scope 3 by FY2030 vs FY2022 baseline.
▾ expand
Dependent: Hard-to-abate value chain investments (single-use plastics, medical waste) Focusing on collaborations to tackle hard-to-abate value chain emissions, including single-use plastics in plasma donation and disposal of regulated medical waste. Plans to enhance circularity in manufacturing (widespread solvent recycling).
▾ expand
Transitioned away from carbon neutrality to focus on decarbonization In fiscal year 2023, Takeda evolved its climate strategy to align with current scientific consensus, transitioning away from carbon neutrality as a climate goal to focus resources on decarbonizing operations and reinvesting in net-zero roadmap initiatives including reducing energy use, switching to renewables, and tackling hard-to-abate value chain emissions.
▾ expand
First BioLife center designed as zero-GHG emissions facility Opened first BioLife plasma donation center in Linz, Austria, designed to operate as a zero-GHG emissions facility.
▾ expand
FY2023 results assured by KPMG AZSA Sustainability Fiscal year 2023 corporate philosophy metric results assured by KPMG AZSA Sustainability Co., Ltd.
▾ expand
see 5 more events →